Processa Pharmaceuticals

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company based in Hanover, Maryland, focused on developing innovative drugs to address unmet medical needs in the United States. The company’s lead candidate, PCS499, is an oral tablet currently undergoing Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic, disfiguring skin condition. Additionally, Processa is advancing PCS12852, a selective 5-HT4 receptor agonist in Phase II trials for post-operative ileus, and PCS6422, an irreversible inhibitor in Phase I trials targeting metastatic colorectal and breast cancer. Furthermore, the company has a licensing agreement with Akashi Therapeutics to develop PCS100, an anti-fibrotic and anti-inflammatory drug. Founded in 2015, Processa seeks to enhance patient survival and quality of life through its targeted drug development efforts.